Xtant Medical Holdings, Inc. (XTNT) — SEC Filings

Xtant Medical Holdings, Inc. (XTNT) — 23 SEC filings. Latest: 10-K (Mar 31, 2026). Includes 10 8-K, 6 10-Q, 3 10-K.

View Xtant Medical Holdings, Inc. on SEC EDGAR

Overview

Xtant Medical Holdings, Inc. (XTNT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Mar 31, 2026: Xtant Medical Holdings, Inc. reported $18.7 million in license revenue in 2025, primarily from its SimpliMax product, which is not expected to recur in 2026 due to changes in reimbursement effective January 1, 2026. This change will also adversely affect a portion of product revenue and gross margin

Sentiment Summary

Across 23 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 19 neutral, 1 mixed. The dominant filing sentiment for Xtant Medical Holdings, Inc. is neutral.

Filing Type Overview

Xtant Medical Holdings, Inc. (XTNT) has filed 3 10-K, 10 8-K, 6 10-Q, 2 DEF 14A, 1 SC 13D/A, 1 SC 13G/A with the SEC between Feb 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent SEC Filings (23)

Xtant Medical Holdings, Inc. SEC Filing History
DateFormDescriptionRisk
Mar 31, 202610-KXtant Medical Divests Assets, Faces $18.7M Revenue Headwind in 2026high
Mar 31, 20268-KXtant Medical Holdings Files 8-K on Financialsmedium
Dec 3, 20258-K8-K Filing
Nov 10, 202510-QXtant Medical Swings to Profit on Surging License Revenue, Cuts Costsmedium
Sep 15, 2025DEF 14AXtant Medical Seeks 12.3M Share Boost for Equity Plan, Board Re-electionmedium
Aug 12, 202510-QXtant Medical Surges 20% in Q2 Product Revenuemedium
Aug 8, 20258-KXtant Medical Holdings Files 8-Kmedium
Aug 4, 20258-KXtant Medical Holdings Reports Director/Officer Changesmedium
Jul 8, 20258-KXtant Medical Holdings Files 8-Kmedium
May 12, 202510-QXtant Medical Holdings Files Q1 2025 10-Qmedium
Apr 16, 20258-KXtant Medical Holdings Reports Key Eventsmedium
Apr 11, 20258-KXtant Medical Holdings Enters Material Definitive Agreementmedium
Mar 6, 202510-KXtant Medical Holdings Files 2024 10-Kmedium
Nov 12, 202410-QXtant Medical Holdings Files Q3 2024 10-Qmedium
Sep 10, 2024SC 13D/AOrbiMed Files 13D/A Amendment for Xtant Medicalmedium
Sep 3, 20248-KXtant Medical Holdings Files 8-Klow
Aug 8, 202410-QXtant Medical Holdings Files Q2 2024 10-Qmedium
Jul 24, 20248-KXtant Medical Holdings Reports Shareholder Vote Matterslow
Jun 10, 2024DEF 14AXtant Medical Holdings Files Definitive Proxy Statementlow
May 15, 202410-QXtant Medical Holdings Files 10-Q for Q1 2024

Risk Profile

Risk Assessment: Of XTNT's 20 recent filings, 1 were flagged as high-risk, 16 as medium-risk, and 3 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Xtant Medical Holdings, Inc. Financial Summary (10-K, Mar 31, 2026)
MetricValue
RevenueN/A
Net IncomeN/A
EPSN/A
Debt-to-EquityN/A
Cash PositionN/A
Operating MarginN/A
Total AssetsN/A
Total DebtN/A

Key Executives

  • Stavros G. Vizirgianakis
  • Sean E. Browne
  • Scott C. Neils

Industry Context

Xtant Medical operates in the global medical technology sector, specifically focusing on orthobiologics and spinal implant fixation systems. The market involves companies developing solutions for spinal fusion, trauma, and other orthopedic applications. Key trends include the development of advanced synthetic bone grafts, biologics for wound closure, and innovative fixation systems, alongside strategic acquisitions and distribution network expansion.

Top Tags

financials (5) · filing (4) · 10-Q (4) · SEC Filing (3) · material-definitive-agreement (3) · Medical Technology (2) · Medical Devices (2) · corporate-governance (2) · 10-K (2) · Financials (2)

Key Numbers

Xtant Medical Holdings, Inc. Key Metrics
MetricValueContext
License Revenue$18.7MRecognized in 2025, not expected to repeat in 2026 due to reimbursement changes.
Coflex/CoFix Divestiture Price$17.5MTotal purchase price for Coflex/CoFix assets sold to Companion Spine, LLC.
Paradigm Divestiture Price$3.9MTotal purchase price for Paradigm Spine GmbH sold to Companion Spine SAS.
Aggregate Divestiture Price$21.4MTotal proceeds from the sale of Coflex/CoFix assets and Paradigm Spine GmbH.
Shares Outstanding140,068,260As of March 25, 2026.
Market Value of Non-Affiliate Common Stock$45.0MAs of June 30, 2025.
Net Income$4.916MNine months ended Sept 30, 2025, compared to -$13.284M loss in prior year.
Total Revenue$101.570MNine months ended Sept 30, 2025, an 18.44% increase from $85.754M.
Product Revenue$27.772MThree months ended Sept 30, 2025, a slight decrease from $27.937M.
Gross Profit$66.519MNine months ended Sept 30, 2025, a 27.45% increase from $52.192M.
Total Operating Expenses$58.291MNine months ended Sept 30, 2025, a 6.56% decrease from $62.384M.
Income from Operations$8.228MNine months ended Sept 30, 2025, a significant improvement from -$10.192M loss.
Cash and Cash Equivalents$10.400MAs of Sept 30, 2025, up from $6.199M at Dec 31, 2024.
Advances from Asset Sale$5.000MReceived from pending sale of Coflex/CoFix assets.
Common Shares Outstanding140,004,240As of November 7, 2025.

Frequently Asked Questions

What are the latest SEC filings for Xtant Medical Holdings, Inc. (XTNT)?

Xtant Medical Holdings, Inc. has 23 recent SEC filings from Feb 2024 to Mar 2026, including 10 8-K, 6 10-Q, 3 10-K. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of XTNT filings?

Across 23 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 19 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Xtant Medical Holdings, Inc. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Xtant Medical Holdings, Inc. (XTNT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Xtant Medical Holdings, Inc.?

Key financial highlights from Xtant Medical Holdings, Inc.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for XTNT?

The investment thesis for XTNT includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Xtant Medical Holdings, Inc.?

Key executives identified across Xtant Medical Holdings, Inc.'s filings include Stavros G. Vizirgianakis, Sean E. Browne, Scott C. Neils.

What are the main risk factors for Xtant Medical Holdings, Inc. stock?

Of XTNT's 20 assessed filings, 1 were flagged high-risk, 16 medium-risk, and 3 low-risk.

What are recent predictions and forward guidance from Xtant Medical Holdings, Inc.?

Forward guidance and predictions for Xtant Medical Holdings, Inc. are extracted from SEC filings as they are enriched.

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.